Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    BCG in the immunotherapy of Hodgkin's disease and non-Hodgkin's lymphomas (1976)
    Springer
    Cancer immunology immunotherapy 1 (1976), S. 109-112 
    Details
    ISSN: 1432-0851
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Patients with bad prognosis malignant lymphomas were treated by a combination of radiotherapy and polychemotherapy. After complete remission they were randomized: one group was treated by BCG in dermic scarification, the other one was not treated. The results do not ascertain BCG efficiency but justify the intensive reductive treatment.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00205302
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    BCG in the immunotherapy of malignant lymphomas (1977)
    Springer
    Cancer immunology immunotherapy 3 (1977), S. 57-60 
    Details
    ISSN: 1432-0851
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The effectiveness of a nonspecific immunostimulation in related human or animal diseases incited us to do a study of nonspecific immunotherapy by BCG in Hodgkin's disease, and then in other malignant lymphomas. Seventy patients, each one fulfilling at least 2 criteria of poor prognosis, were initially put in complete remission by a combination of radio-chemotherapy, followed by a reinforcing chemotherapy. These patients were then randomized into two groups. The first group received no further treatment; the second received BCG in weekly cutaneous scarifications. Eight patients were excluded from the study. The rate of relapses is significantly lower in the treated group. The results are discussed. Other therapeutic studies are necessary to fix the indications and modalities of this immunotherapy.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00199326
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Chimiothérapie de la maladie de Hodgkin associant procarbazine, vinblastine, cyclophosphamide et méthyl-prednisolone (1973)
    Springer
    Journal of cancer research and clinical oncology 80 (1973), S. 179-188 
    Details
    ISSN: 1432-1335
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Résumé Les auteurs analysent 124 cures de chimiothérapie associant vinblastine, procarbazine, cyclophosphamide et méthyl-prednisolone réalisées chez 90 malades atteints de maladie de Hodgkin. Ce traitement, appliqué à des malades hospitalisés, dure en principe trois semaines. L'intolérance, surtout hématologique (leucocytose inférieure à 2000μl) a conduit à abréger la cure dans près de la moitié des cas, mais, rapidement réversible, elle n'a gêné la réalisation d'une irradiation ultérieure que dans deux cas sur 81. Pour 101 cures interprétables, on a observé 10 échecs non totaux, 88 rémissions partielles dont 32 inférieures à 50% et 56 supérieures à 50% et 3 rémissions complètes. Un seul échec a été enregistré chez les 51 malades vierges de traitement. La place de ce traitement dans la stratégie du traitement de la maladie de Hodgkin est discutée et son intérêt souligné en tant que moyen pratique et efficace.
    Notes: Summary Ninety patients with Hodgkin's disease have received 124 courses of chemotherapy with vinblastine, procarbazine, cyclophosphamide and methyl-prednisolone. The treatment is given during a period of 2–3 weeks to hospitalized patients. The main toxicity is haematological and the course is stopped when the leucocytosis is to 2000μl or less. This chemotherapy has allowed a subsequent irradiation in all but 2 among 81 cases. For 101 evaluable courses there were 10 incomplete failures, 32 remissions of less than 50%, 56 remissions of more than 50% and 3 complete remissions. There was only one failure among 51 patients without previous treatment. The place of this chemotherapy in the therapeutic strategy of Hodgkin's disease is discussed.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00305134
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Semen analysis and cryoconservation before treatment in Hodgkin's disease (2000)
    Springer
    Annals of oncology 11 (2000), S. 679-684 
    Details
    ISSN: 1569-8041
    Keywords: cryopreservation ; Hodgkin's disease ; sterility
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background:The prophylaxis of the late effects of chemotherapyand radiotherapy has become one of the major concerns in the management ofHodgkin's disease (HD). Unlike other complications, male sterility could bemanaged by prior semen preservation (SP). Patients and methods:To evaluate the semen quality of patientswith HD and the outcome of insemination, we reviewed spermograms of patientswho underwent SP before any treatment. The following criteria were necessary:1) age 〉16 and 〈50; 2) HD of any stage; 3) informed about male sterilityafter HD treatment; 4) fully consenting. Results:Such a proposal was made to 316 men, and 94 fulfilled thecriteria. All patients underwent an initial chemotherapy. Mean age of thecohort was 27.5 years (range 16–48 years). Pretherapeutic staging of HDrevealed 38 stage I (40%), 38 II (38%), 14 III (15%) and4 IV (4%). Semen analysis before cryoconservation showed an overall53% of normal or subnormal cases (50 cases). The analysis of semenquality and spermatozoid amount according to various parameters failed to finda correlation with stage, B symptoms, age, or biologic data (LDH, WBC,platelets, ESR). The use of cryopreserved semen was requested by 13 patients;88 inseminations were performed leading to 9 pregnancies and 2 births. Conclusions:The low rate of success with cryopreserved semen inthese cases suggests the need for a more careful design of non-toxicchemotherapy regimens in combined modality treatment.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008353728560
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    Novel combination of epirubicin, bleomycin, vinblastine and prednisone (EBVP II) before radical radiotherapy in localized stages (I-IIIA) of Hodgkin's disease (1991)
    Springer
    Journal of cancer research and clinical oncology 117 (1991), S. 377-380 
    Details
    ISSN: 1432-1335
    Keywords: Hodgkin's disease ; Chemotherapy ; Combination
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary A novel combination of epirubicin, bleomycin, vinblastine and prednisone (EBVP II) was scheduled to reduce the toxicity of chemotherapy and to improve its application in treatment of Hodgkin's disease. This combination followed a previous regimen given every 15 days (EBVP I) by the same cooperative group. EPVP II is given every 21 days with increased dosage and increased intensity of epirubicin. This regimen was given to 100 consecutive patients with favourable or unfavourable limited-stage disease (clinical stages I-IIIA) excluding very favourable stages I and II and stages IIIB and IV. Such patients first received three injections of EBVP II and were then radically irradiated; those with unfavourable prognosis factors received three subsequent injections of EBVP II. The present analysis reports the early results of such treatment and considers particularly toxicity and the obtention of complete remission, which is preeminent for a cure. EBVP II was given in full dosage in 99% of the primary set of three injections. The main toxicity was alopecia and to a lesser degree nausea and vomiting and veinitis. Complete remission was obtained in 76 patients before radiotherapy and in 20 others after radiotherapy. With a median follow-up of 30 months 1 patient died from Hodgkin's disease, 9 are alive after relapse and 90 with no evidence of disease. This treatment appears to be as efficient as previous chemotherapy, well tolerated and particularly easy to give. It deserves further comparison with other proved regimens taking into consideration the survival and quality of life of patients.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01630723
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...